Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): A randomised, double-blind, placebo-controlled phase 3 trial

The Lancet Oncology

Volumn 15, Issue 6, 2014, Pages 580-591

  André, Fabrice ^a   O'Regan, Ruth ^b   Ozguroglu, Mustafa ^c   Toi, Masakazu ^d   Xu, Binghe ^e   Jerusalem, Guy ^f   Masuda, Norikazu ^g   Wilks, Sharon ^h   Arena, Francis ⁱ   Isaacs, Claudine ^j   Yap, Yoon Sim ^k   Papai, Zsuzsanna ^l   Lang, Istvan ^m   Armstrong, Anne ⁿ   Lerzo, Guillermo ^o   White, Michelle ^p,q   Shen, Kunwei ^r   Litton, Jennifer ^s   Chen, David ^t   Zhang, Yufen ^t   Ali, Shyanne ^t   Taran, Tetiana ^t   Gianni, Luca ^u   more..

^a Universite Paris Sud   (France)

^b EMORY UNIVERSITY   (United States)

^c ISTANBUL UNIVERSITY   (Turkey)

^d KYOTO UNIVERSITY   (Japan)

^e CANCER HOSPITAL   (China)

^f UNIVERSITY OF LIÈGE   (Belgium)

^g OSAKA NATIONAL HOSPITAL   (Japan)

^h Cancer Care Centers of South Texas   (United States)

ⁱ NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^j GEORGETOWN UNIVERSITY   (United States)

^k DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^l Military Hospital State Health Centre Oncology Department   (Hungary)

^m NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

ⁿ CHRISTIE HOSPITAL   (United Kingdom)

^o Sanatorio de la Providencia   (Argentina)

^p MONASH MEDICAL CENTRE   (Australia)

^q CABRINI INSTITUTE   (Australia)

^r SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^s UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^t NOVARTIS PHARMA AG   (Switzerland)

^u SAN RAFFAELE HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; NAVELBINE; PLACEBO; TRASTUZUMAB;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; AGED; AGRANULOCYTOSIS; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BONE PAIN; BREAST CANCER; BREAST CARCINOMA; CANCER FATIGUE; CANCER SURVIVAL; CATARACT; CELLULITIS; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; COUGHING; DECREASED APPETITE; DEVICE INFECTION; DIABETES MELLITUS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; DYSPNEA; EPISTAXIS; FAINTNESS; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; GASTROENTERITIS; GRANULOCYTOPENIA; HEADACHE; HERPES ZOSTER; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; HYPOXIA; INSOMNIA; INTENTION TO TREAT ANALYSIS; INTERSTITIAL LUNG DISEASE; LETHARGY; LEUKOPENIA; LUNG EMBOLISM; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MOUTH ULCER; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SEPSIS; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; VERY ELDERLY; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, ERBB-2; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SIROLIMUS; TREATMENT OUTCOME;

EID: 84899992665     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70138-X     Document Type: Article

References (37)

1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
2. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
3. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:1800-1808.
4. Montemurro F, Donadio M, Clavarezza M, et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist 2006, 11:318-324.
5. Bartsch R, Wenzel C, Altorjai G, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 2007, 25:3853-3858.
6. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010, 28:1124-1130.
7. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743.
8. NCCN clinical practice guidelines in oncology (NCCN Guidelines®) for breast cancer, V.2.2014 National Comprehensive Cancer Network, (accessed March 31, 2014). http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
9. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012, 367:1783-1791.
10. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010, 28:1138-1144.
11. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
12. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
13. Pandolfi PP Breast cancer-loss of PTEN predicts resistance to treatment. N Engl J Med 2004, 351:2337-2338.
14. Wang L, Zhang Q, Zhang J, et al. PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer 2011, 11:248.
15. Steelman LS, Chappell WH, Abrams SL, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging 2011, 3:192-222.
16. Lu CH, Wyszomierski SL, Tseng LM, et al. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 2007, 13:5883-5888.
17. Mondesire WH, Jian W, Zhang H, et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 2004, 10:7031-7042.
18. Zhu Y, Zhang X, Liu Y, et al. Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo. Tumour Biol 2012, 33:1349-1362.
19. Jerusalem G, Fasolo A, Dieras V, et al. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 2011, 125:447-455.
20. Andre F, Campone M, O'Regan R, et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 2010, 28:5110-5115.
21. Morrow PK, Wulf GM, Ensor J, et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol 2011, 29:3126-3132.
22. Andersson M, Lidbrink E, Bjerre K, et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol 2011, 29:264-271.
23. Burstein HJ, Keshaviah A, Baron AD, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 2007, 110:965-972.
24. Baselga J, Segalla JG, Roche H, et al. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol 2012, 30:1484-1491.
25. Mayer EL, Dhakil S, Patel T, et al. SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol 2010, 21:2370-2376.
26. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012, 366:520-529.
27. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010, 116:4256-4265.
28. Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR+ breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 2013, 30:870-884.
29. Bhargava R, Dabbs DJ, Beriwal S, et al. Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer. Mod Pathol 2011, 24:367-374.
30. Nahta R, O'Regan RM Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers. Breast Cancer Res Treat 2012, 135:39-48.
31. Viale G, Regan MM, Dell'Orto P, et al. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol 2010, 22:2201-2207. BIG 1-98 Collaborative and International Breast Cancer Study Groups.
32. Chandarlapaty S, Sakr RA, Giri D, et al. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clin Cancer Res 2012, 18:6784-6791.
33. Esteva FJ, Guo H, Zhang S, et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 2010, 177:1647-1656.
34. Perez EA, Dueck AC, McCullough AE, et al. Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 Trial. J Clin Oncol 2013, 31:2115-2122.
35. Razis E, Bobos M, Kotoula V, et al. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat 2011, 128:447-456.
36. Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINEO study. J Clin Oncol 2012, 30:2718-2724.
37. Baselga J, Cortés J, Kim S-B, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012, 366:109-119. for the CLEOPATRA Study Group.